TY - JOUR AU - Vigneault, Éric AU - Savard, Josée AU - Savard, Marie-Hélène AU - Ivers, Hans AU - Després, Philippe AU - Foster, William AU - Martin, André-Guy AU - Fradet, Vincent PY - 2017/11/01 Y2 - 2024/03/28 TI - Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population JF - Canadian Urological Association Journal JA - CUAJ VL - 11 IS - 12 SE - Original Research DO - 10.5489/cuaj.4428 UR - https://cuaj.ca/index.php/journal/article/view/4428 SP - 404-10 AB - <p><strong>Introduction:</strong> This study aims to empirically validate the French- Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients.</p><p><strong>Methods:</strong> Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer.</p><p><strong>Results:</strong> The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach’s alpha coefficients from 0.80‒0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15‒0.85), and temporal stability (rs=0.72‒0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56‒0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p&lt;0.05) between pre- and post-prostate cancer treatment.</p><p><strong>Conclusions:</strong> The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancer patients.</p> ER -